​

SpringWorks Therapeutics (SWTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SWTX Stock Forecast

SpringWorks Therapeutics (SWTX) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $77.00, with a high of $78.00 and a low of $76.00. This represents a 110.84% increase from the last price of $36.52.

$30 $40 $50 $60 $70 $80 High: $78 Avg: $77 Low: $76 Last Closed Price: $36.52

SWTX Stock Rating

SpringWorks Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

SWTX Forecast vs Benchmarks

TypeNameUpside
StockSpringWorks Therapeutics110.84%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts112
Avg Price Target$78.00$78.00$77.00
Last Closing Price$36.52$36.52$36.52
Upside/Downside113.58%113.58%110.84%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2535---8
Dec, 2445---9
Nov, 2445---9
Oct, 2445---9
Sep, 2445---9
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 08, 2025Michael SchmidtGuggenheim$78.00$41.2089.32%113.58%
Aug 08, 2024Robert BurnsH.C. Wainwright$76.00$33.93123.99%108.11%
Aug 09, 2022H.C. Wainwright$94.00$39.66137.01%157.39%
May 27, 2022Wedbush$50.00$18.72167.09%36.91%
May 24, 2022Goldman Sachs$76.00$32.74132.13%108.11%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Jan 08, 2025GuggenheimBuyBuyhold
Aug 08, 2024H.C. WainwrightBuyBuyhold
Jun 18, 2022H.C. WainwrightBuyBuyhold
May 27, 2022WedbushOutperformOutperformhold
May 24, 2022Goldman SachsBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.02$-3.57$-0.01-----
Avg Forecast$-1.37$-3.11$-4.92$-3.12$-2.12$-1.01$2.49$4.35
High Forecast$-1.61$-3.67$-5.34$-3.23$-3.36$-2.09$0.30$3.73
Low Forecast$-1.07$-2.44$-4.77$-2.93$-0.66$0.24$3.75$5.51
Surprise %-25.55%14.79%-99.80%-----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$35.00M-$5.45M-----
Avg Forecast$21.00M$180.00$1.01M$186.88M$348.09M$588.47M$919.88M$1.16B
High Forecast$17.52M$144.00$583.21K$165.83M$309.17M$523.79M$818.78M$1.03B
Low Forecast$23.86M$216.00$1.84M$196.94M$418.56M$709.12M$1.11B$1.39B
Surprise %66.67%-441.11%-----

Net Income Forecast

$-350M $-210M $-70M $70M $210M $350M Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-44.24M$-173.21M$-325.10M-----
Avg Forecast$907.63K$-128.42M$-325.10M$-194.19M$-147.81M$-44.49M$192.32M$274.59M
High Forecast$-19.20M$-154.10M$-337.05M$-203.68M$-212.18M$-132.09M$18.94M$235.36M
Low Forecast$21.02M$-102.73M$-301.25M$-184.71M$-41.54M$14.91M$236.71M$347.78M
Surprise %-4974.66%34.88%------

SWTX Forecast FAQ

Is SpringWorks Therapeutics stock a buy?

SpringWorks Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that SpringWorks Therapeutics is a favorable investment for most analysts.

What is SpringWorks Therapeutics's price target?

SpringWorks Therapeutics's price target, set by 4 Wall Street analysts, averages $77 over the next 12 months. The price target range spans from $76 at the low end to $78 at the high end, suggesting a potential 110.84% change from the previous close price of $36.52.

How does SpringWorks Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

SpringWorks Therapeutics stock forecast shows a 110.84% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for SpringWorks Therapeutics over the past three months?

  • January 2025: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 44.44% Strong Buy, 55.56% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 44.44% Strong Buy, 55.56% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is SpringWorks Therapeutics’s EPS forecast?

SpringWorks Therapeutics's average annual EPS forecast for its fiscal year ending in December is -3.12 for 2024, a 31100.00% increase from the reported $-0.01 in 2023. The prediction for 2025 is $-2.12, $-1.01 for 2026, $2.49 for 2027, and $4.35 for 2028.

What is SpringWorks Therapeutics’s revenue forecast?

SpringWorks Therapeutics's average annual revenue forecast for its fiscal year ending in December is $186.88M for 2024, a 3330.97% increase from the reported $5.45M in 2023. The forecast for 2025 is $348.09M, $588.47M for 2026, $919.88M for 2027, and $1.16B for 2028.

What is SpringWorks Therapeutics’s net income forecast?

For its fiscal year ending in December, SpringWorks Therapeutics's average annual net income forecast is $-194M for 2024, reflecting a -40.27% decrease from the reported $-325M in 2023. The projection for 2025 is $-148M, $-44.487M for 2026, $192.32M for 2027, and $274.59M for 2028.